NEW YORK (GenomeWeb News) — The Children's Hospital of Philadelphia will use Affymetrix’s newly released Genome-Wide Human SNP Array 6.0 in whole-genome studies aiming to identify genes responsible for cardiovascular, metabolic, and central nervous system disorders, Affy said today.
CHOP researchers will initially run studies on DNA taken from 7,000 individuals and plan to increase the genome-wide studies with outside collaborators. Affy’s 6.0 SNP array, launched in May, measures 1.8 million markers for genetic variations, the company said.
Hakon Hakonarson, director of CHOP’s Center for Applied Genomics, said the Affy array allows researchers to genotype “more markers at a lower cost per sample,” and it increases the chance of finding genes that are linked to diseases or to adverse drug responses.
“The results from these projects will open the door to new genetic studies and help us extend current collaborations with other investigators around the world," Hakonarson said.
Financial terms of the agreement were not released.